Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Launching of 2D Barcode Implementation on Pharmaceuticals Products and Starting the Pilot Phase in 2018

 
The Ministry of Public health has launched the pilot phase for 2D data Matrix Barcode Implementation on pharmaceutical products in the auditorium of the Ministry in Bir Hassan, under the patronage of Deputy Prime Minister Health Minister Ghassan Hasbani and in the presence of Director General of the Ministry Dr. Walid Ammar, the President of the Lebanese Order of Parmacists Georges Sili, the President of the Syndicate of Pharmaceutical Industries Caroline Abi Karam, the president of the Lebanese Pharmaceutical Importers Association Armond Phares, the President of the Syndicate of Hospital Owners Sleiman Haroun, the President of the Order of Physicians Raymond Sayegh, The Director of the Medical Care Directorate Dr. Joseph El-Helou, WHO representative Dr. Alissar Radi, Director of  E-Health program at the Ministry Lina Abou Mrad, and a number of representatives of hospitals and pharmaceutical industries.

The Director General Dr. Walid ammar explained the strategic frame of the project that comes within the Lebanese pharmaceutical sector reform and improvement plan. This project is achieved by reconsidering the legislations, regulating the registration and pricing of drugs, developing standards and programs to ensure quality in order to provide the patients with a safe quality-assured drug at the right price.

Mrs. Lina Abou Mrad then announced the launch of the implementation of 2D Barcode in 2018, while explaining the requirements of the information system that was lately developed to track the drugs across the supply chain, from manufacturing phase to sale to patients. Mrs Abou Mrad outlined as well the timeline for the implementation phase.

Hasbani

Hasbani said it was a pleasure to launch a new step for a long path of technology implementation to improve the performance of the healthcare sector. “Today we are launching the pilot phase for 2D barcode implementation that aims at ensuring the patient’s access to the safe drug, tracking drugs across the traceability supply chain, controlling illegal drugs and speeding up drugs recall from the Lebanese market and reimbursement of patients affiliated to insurers”, he added.
    1
ATC ↓ Name B/G Ingredients Dosage Form Price
R06AB52 HISTAMED-F G Dexchlorpheniramine - 2mg/5ml, Dexamethasone - 0.25mg/5ml Syrup 712,876 L.L
R06AB52 HISTAMED-F G Dexchlorpheniramine maleate - 2mg, Dexamethasone - 0.25mg, Fluphenazine HCl - 0.25mg Tablet, coated 579,772 L.L
R06AB02 HISTAMED G Dexchlorpheniramine maleate - 1% 1% Gel 477,384 L.L
R06AA52 HISTALIX G Diphenhydramine HCl - 14mg/5ml, Ammonium chloride - 135mg/5ml, Menthol - 1.1mg/5ml Syrup 405,840 L.L
R05CA12 HEDERAL G Dried Ivy leaf extract (Hedera Helix) - 99mg/5ml 99mg/5ml Drops solution 384,339 L.L
R05CA12 HEDERAL G Dried Ivy leaf extract - 37mg/5ml 37mg/5ml Syrup 309,084 L.L
R05CA12 HEDECTON COUGH G Ivy leaf soft extract - 40mg/5ml Syrup 467,657 L.L
R02AA20 HEXASPRAY COLLUTOIRE PRESSURISE B Biclotymol - 750mg 750mg Spray 353,431 L.L
N05CD08 HIKMA MIDAZOLAM G Midazolam (HCl) - 5mg/ml 5mg/ml Injectable solution 679,984 L.L
N05AD01 HALOPERIDOL G Haloperidol - 5mg 5mg Tablet 276,448 L.L
N05AD01 HALOPERIDOL G Haloperidol - 2mg 2mg Tablet 252,130 L.L
N05AD01 HALOPERIDOL G Haloperidol - 10mg 10mg Tablet 339,160 L.L
N05AD01 HALOPERIDOL G Haloperidol - 20mg 20mg Tablet 339,160 L.L
N02BE51 HUMACE PLUS G Paracetamol - 500mg, Aceclofenac (potassium) - 200mg Tablet 575,165 L.L
N02BE51 HUMEXLIB PARACETAMOL CHLORPHENAMINE B Paracetamol - 500mg, Chlorphenamine maleate - 4mg Capsule 598,010 L.L
N02BE51 HUMEX RHUME B Pseudoephedrine HCl (tablet) - 60mg, Paracetamol (tablet) - 500mg, Paracetamol (capsule) - 500mg, Chlorphenamine maleate (capsule) - 4mg Tablet, capsule 467,657 L.L
M09AX01 HYALGAN B Hyaluronic acid (sodium) - 20mg/2ml 20mg/2ml Injectable solution 3,407,985 L.L
M01AE03 HUMFINE G Ketoprofen - 100mg/2ml 100mg/2ml Injectable solution 3,514,148 L.L
L04AB04 HUMIRA BioTech Adalimumab - 40mg/0.4ml 40mg/0.4ml Injectable solution 34,045,375 L.L
L04AB04 HYRIMOZ BioTech Adalimumab - 40mg 40mg Injectable solution 19,536,163 L.L
L04AB04 HYRIMOZ BioTech Adalimumab - 40mg 40mg Injectable solution 19,536,163 L.L
L04AB04 HYRIMOZ BioTech Adalimumab - 40mg/0.4ml 40mg/0.4ml Injectable solution 52,871,023 L.L
L04AB04 HYRIMOZ BioTech Adalimumab - 40mg/0.4ml 40mg/0.4ml Injectable solution 52,871,023 L.L
L04AB04 HUMIRA BioTech Adalimumab - 40mg/0.4ml 40mg/0.4ml Injectable solution L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution 18,792,549 L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution L.L
L01FD01 HERCEPTIN BioTech Trastuzumab - 440mg 21mg/ml Injectable concentrated powder for solution+diluent 166,423,476 L.L
L01FD01 HERCEPTIN BioTech Trastuzumab - 440mg 21mg/ml Injectable concentrated powder for solution+diluent 166,423,476 L.L
L01FD01 HERZUMA BioTech Trastuzumab - 440mg 440mg Injectable powder for concentrate for solution 82,195,925 L.L
L01FD01 HERZUMA BioTech Trastuzumab - 150mg 150mg Injectable powder for concentrate for solution 35,873,919 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026